NFLX Stock
NFLX Stock

Generation Bio Co. (GBIO) stock plunged 55.86% in the current-market trading session at the price of $6.14 after it published updates on preclinical studies for Hemophilia A Program. GBIO is formulating genetic medicines to provide long-lasting treatments for patients with rare and prevalent conditions.  

GBIO Published Updates on Hemophilia A Program 

On 14th December 2021, GBIO presented updates on non-human primate (NHP) clinical studies for hemophilia A. The company has also provided updates on the progress of its non-viral genetic medicine.

Generation Bio’s genetic medicine technology contains a closed-ended DNA delivered via a cell-targeted lipid nanoparticle (ctLNP). The company would incorporate the rapid enzymatic synthesis into its product pipelines for ceDNA production. The rapid enzymatic synthesis (RES) has increased ceDNA purity to 99%. The company hopes to publish more updates from its pipeline programs in 2022.   

Management Comments  

Chief scientific officer of GBIO, Matthew Stanton, remarked that they had made considerable progress in this platform. RES has produced highly pure ceDNA across a wide range of manufacturing scales. The company had devised new production procedures that enabled significant improvements in the consistency of its ctLNPs. These novel analytical methods have provided more insights to advance novel proprietary ctLNPs to meet the target profile for a hemophilia A program.  

Chief executive officer of GBIO, Geoff McDonough, commented that they are inventing genetic medicines to surpass the limits of traditional gene therapies and to influence the lives of millions of patients. The company has a long history of directing systemic DNA delivery to create a novel non-viral genetic medicine forum. They believe that the vigor and creativity of their technology will unlock the potential of genetic medicine. They have a strong balance sheet and a fantastic team to continue this program, he added.   

GBIO Third Quarter 2021 Financial Results 

On 10th November 2021, GBIO reported its earnings report for the third quarter of 2021. Net loss amounted $31.9 million, or per share of $0.56, for the third quarter ended 30th September 2021. For the third quarter of 2020, the net loss was approximately $20.8 million. The company has cash and cash equivalents of $398.4 million on 30th September 2021.

LEAVE A REPLY

Please enter your comment!
Please enter your name here